| Bioactivity | LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC50 of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease[1]. |
| Target | IC50: 2.6 nM (LRRK2) |
| In Vivo | LRRK2-IN-4 (compound 24) (p.o.) shows good oral bioavailability in male Wistar-Han rats (F=64%), male beagle dogs (F=65%)[1]. |
| Name | LRRK2-IN-4 |
| CAS | 2641054-59-1 |
| Formula | C25H29ClF2N6O2 |
| Molar Mass | 518.99 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Keylor MH, et al. Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors. J Med Chem. 2022; 65(1):838-856. |
LRRK2-IN-4
CAS: 2641054-59-1 F: C25H29ClF2N6O2 W: 518.99
LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.